SCHEMBL29308170

SCHEMBL29308170

CC(C)(C)OC(=O)[C@@H]1C[C@H](O)CN1

nearest known ligand 0.41

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 4/20 0.41
DPP8 Q6V1X1 4/20 0.41
DPP9 Q86TI2 4/20 0.41
CHRM2 P08172 1/20 0.39
CHRM1 P11229 1/20 0.39
CHRM3 P20309 1/20 0.39
SMYD3 Q9H7B4 1/20 0.33
MAPK1 P28482 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.32
CYP1A2 P05177 1/20 0.31
CYP2D6 P10635 1/20 0.31
ALOX15 P16050 1/20 0.31
CYP2C19 P33261 1/20 0.31
SLC1A3 P43003 1/20 0.31
SLC1A2 P43004 1/20 0.31
SLC1A1 P43005 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL695946 1.00 DPP4 (0.41) DPP4DPP8DPP9CHRM2CHRM1
SCHEMBL21673908 1.00 DPP4 (0.41) DPP4DPP8DPP9CHRM2CHRM1
SCHEMBL28146362 1.00 DPP4 (0.41) DPP4DPP8DPP9CHRM2CHRM1
SCHEMBL4017978 1.00 DPP4 (0.41) DPP4DPP8DPP9CHRM2CHRM1
Hydrochloric Acid SCHEMBL30914110 0.98 DPP4 (0.40) DPP4DPP8DPP9CHRM2CHRM1
SCHEMBL4463526 0.86 DPP4 (0.37) DPP4DPP8DPP9CHRM2CHRM1
SCHEMBL3997238 0.86 DPP4 (0.37) DPP4DPP8DPP9CHRM2CHRM1
SCHEMBL9949501 0.84 CHRM2 (0.41) DPP4DPP8DPP9CHRM2CHRM1
SCHEMBL9949495 0.84 CHRM2 (0.41) DPP4DPP8DPP9CHRM2CHRM1
SCHEMBL4559703 0.82 DPP4 (0.38) DPP4DPP8DPP9CHRM2CHRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12037415-B2 Peptide and pharmaceutical composition for treating an eye disease comprising the same as an active pharmaceutical ingredient YUYU PHARMA, INC. (KR) 2024-07-16 US disclosed
US-12037415-B2 Peptide and pharmaceutical composition for treating an eye disease comprising the same as an active pharmaceutical ingredient YUYU PHARMA, INC. (KR) 2024-07-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12037415-B2 Peptide and pharmaceutical composition for treating an eye disease comprising the same as an active pharmaceutical ingredient VIP, IAPP, NGLY1 DPP4 433/4885DPP8 461/4885DPP9 163/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.